Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020
Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.
Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 6, 1, 5, 9, 6 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Chemotherapy Induced Neutropenia - Overview
Chemotherapy Induced Neutropenia - Therapeutics Development
Chemotherapy Induced Neutropenia - Therapeutics Assessment
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
Chemotherapy Induced Neutropenia - Drug Profiles
Chemotherapy Induced Neutropenia - Dormant Projects
Chemotherapy Induced Neutropenia - Discontinued Products
Chemotherapy Induced Neutropenia - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Enzychem Lifesciences Corp, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by FortuneRock (China) Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by General Regeneratives Shanghai Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Ilkogen Ilac San Ve Tic AS, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corp, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Profarma, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Shandong New Time Pharmaceutical Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Siam Bioscience Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Tanvex BioPharma Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by UBI Pharma Inc, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Valenta Pharm, H1 2020
Chemotherapy Induced Neutropenia - Pipeline by Xiamen Amoytop Biotech Co Ltd, H1 2020
Chemotherapy Induced Neutropenia - Dormant Projects, H1 2020
Chemotherapy Induced Neutropenia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Chemotherapy Induced Neutropenia - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned
Apotex Inc
BeyondSpring Inc
Biocon Ltd
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Dr. Reddy's Laboratories Ltd
Enzychem Lifesciences Corp
FortuneRock (China) Ltd
Gene Techno Science Co Ltd
General Regeneratives Shanghai Ltd
Generon (Shanghai) Corp Ltd
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
Ilkogen Ilac San Ve Tic AS
Jiangsu Aosaikang Pharmaceutical Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Lupin Ltd
Mycenax Biotech Inc
Nohla Therapeutics Inc
Pangen Biotech Inc
Pfizer Inc
PharmaEssentia Corp
Profarma
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Shandong New Time Pharmaceutical Co Ltd
Siam Bioscience Co Ltd
Tanvex BioPharma Inc
UBI Pharma Inc
USV Pvt Ltd
Valenta Pharm
Xiamen Amoytop Biotech Co Ltd
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets